Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ

被引:51
作者
Namba, R
Young, LJT
Maglione, JE
McGoldrick, ET
Liu, S
Wurz, GT
DeGregorio, MW
Borowsky, AD
MacLeod, CL
Cardiff, RD
Gregg, JP [1 ]
机构
[1] Univ Calif Davis, Sch Med, Dept Pathol & Lab Med, Sacramento, CA 95817 USA
[2] Univ Calif Davis, Sch Med, Dept Internal Med, Div Hematol & Oncol, Sacramento, CA 95817 USA
[3] Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA
[4] Univ Calif San Diego, Sch Med, UCSD Canc Ctr, Dept Med, La Jolla, CA 92093 USA
来源
BREAST CANCER RESEARCH | 2005年 / 7卷 / 06期
关键词
D O I
10.1186/bcr1317
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Ductal carcinoma in situ ( DCIS) is a noninvasive premalignant lesion and is considered a precursor to invasive carcinoma. DCIS accounts for nearly 20% of newly diagnosed breast cancer, but the lack of experimentally amenable in vivo DCIS models hinders the development of treatment strategies. Here, we demonstrate the utility of a mouse transplantation model of DCIS for chemoprevention studies using selective estrogen receptor modulators ( SERMs). This model consists of a set of serially transplanted lines of genetically engineered mouse mammary intraepithelial neoplasia (MIN) outgrowth (MIN-O) tissue that have stable characteristics. We studied the ovarian-hormone-responsiveness of one of the lines with a particular focus on the effects of two related SERMs, tamoxifen and ospemifene. Methods The estrogen receptor ( ER) status and ovarian-hormone-dependence of the mouse MIN outgrowth tissue were determined by immunohistochemistry and ovarian ablation. The effects of tamoxifen and ospemifene on the growth and tumorigenesis of MIN outgrowth were assessed at 3 and 10 weeks after transplantation. The effects on ER status, cell proliferation, and apoptosis were studied with immunohistochemistry. Results The MIN-O was ER-positive and ovarian ablation resulted in reduced MIN-O growth and tumor development. Likewise, tamoxifen and ospemifene treatments decreased the MIN growth and tumor incidence in comparison with the control ( P < 0.01). Both SERMs significantly decreased cell proliferation. Between the two SERM treatment groups, there were no statistically significant differences in MIN-O size, tumor latency, or proliferation rate. In contrast, the ospemifene treatment significantly increased ER levels while tamoxifen significantly decreased them. Conclusion Tamoxifen and ospemifene inhibit the growth of premalignant mammary lesions and the progression to invasive carcinoma in a transplantable mouse model of DCIS. The inhibitory effects of these two SERMs are similar except for their effects on ER modulation. These differences in ER modulation may suggest different mechanisms of action between the two related SERMs and may portend different long-term outcomes. These data demonstrate the value of this model system for preclinical testing of antiestrogen or other therapies designed to prevent or delay the malignant transformation of premalignant mammary lesions in chemoprevention.
引用
收藏
页码:R881 / R889
页数:9
相关论文
共 34 条
[1]  
Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558
[2]   A RANDOMIZED COMPARISON OF TAMOXIFEN WITH SURGICAL OOPHORECTOMY IN PREMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER [J].
BUCHANAN, RB ;
BLAMEY, RW ;
DURRANT, KR ;
HOWELL, A ;
PATERSON, AG ;
PREECE, PE ;
SMITH, DC ;
WILLIAMS, CJ ;
WILSON, RG .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (09) :1326-1330
[3]   The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting [J].
Cardiff, RD ;
Anver, MR ;
Gusterson, BA ;
Hennighausen, L ;
Jensen, RA ;
Merino, MJ ;
Rehm, S ;
Russo, J ;
Tavassoli, FA ;
Wakefield, LM ;
Ward, JM ;
Green, JE .
ONCOGENE, 2000, 19 (08) :968-988
[4]   Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat [J].
Carthew, P ;
Lee, PN ;
Edwards, RE ;
Heydon, RT ;
Nolan, BM ;
Martin, EA .
ARCHIVES OF TOXICOLOGY, 2001, 75 (06) :375-380
[5]  
Clarke M, 1998, LANCET, V351, P1451
[6]   An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer [J].
Crump, M ;
Sawka, CA ;
DeBoer, G ;
Buchanan, RB ;
Ingle, JN ;
Forbes, J ;
Meakin, JW ;
Shelley, W ;
Pritchard, KI .
BREAST CANCER RESEARCH AND TREATMENT, 1997, 44 (03) :201-210
[7]   Treatment of DCIS - results from clinical trials [J].
Cuzick, J .
SURGICAL ONCOLOGY-OXFORD, 2003, 12 (04) :213-219
[8]   Estradiol promotes growth and angiogenesis in polyoma middle T transgenic mouse mammary tumor explants [J].
Dabrosin, C ;
Palmer, K ;
Muller, WJ ;
Gauldie, J .
BREAST CANCER RESEARCH AND TREATMENT, 2003, 78 (01) :1-6
[9]   Initiating oncogenic event determines gene-expression patterns of human breast cancer models [J].
Desai, KV ;
Xiao, N ;
Wang, W ;
Gangi, L ;
Greene, J ;
Powell, JI ;
Dickson, R ;
Furth, P ;
Hunter, K ;
Kucherlapati, R ;
Simon, R ;
Liu, ET ;
Green, JE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (10) :6967-6972
[10]   Polyoma virus middle T antigen and its role in identifying cancer-related molecules [J].
Dilworth, SM .
NATURE REVIEWS CANCER, 2002, 2 (12) :951-956